Previous close | 0.5155 |
Open | 0.5081 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.4715 - 0.5200 |
52-week range | 0.1401 - 0.7398 |
Volume | |
Avg. volume | 33,449 |
Market cap | 77.883M |
Beta (5Y monthly) | 3.36 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
VANCOUVER, British Columbia, April 04, 2024--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) ("Alpha Cognition," or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended 2023 and provided a corporate update.
MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compani
VANCOUVER, British Columbia, March 20, 2024--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it will present at the Emerging Growth Conference on April 3, 2024. The company invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.